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Abstract
Background: Intravitreal injection is widely used to treat retinal vein occlusion, and acute angle closure (AAC) is an
exceptional complication of intravitreal injection. The authors report a case of AAC that occurred immediately after
administering intravitreal bevacizumab to treat branch retinal vein occlusion (BRVO).
Case presentation: A 65-year-old woman was referred to the retina clinic of a tertiary referral center for the
treatment of macular edema secondary to BRVO. On slit lamp examination, anterior chamber (AC) depth was
shallow (3 corneal thicknesses centrally, 1/4 corneal thicknesses peripherally) in both eyes. Intraocular pressure
(IOP) was 19 mmHg in both eyes, and refractive error was +1.00 diopter sphere in both eyes. A gonioscopy
exam demonstrated narrow angle of over 180° in both eyes. To treat the macular edema, bevacizumab was
injected into her right eye intravitreally. After two bevacizumab injections, the macular edema regressed but
recurred 5 months later, and thus, a third injection was performed. The next day, she visited our emergency
department complaining of persistent ocular pain in her right eye. The right pupil had dilated to 6 mm
diameter and was fixed. Slit lamp exam revealed diffuse corneal edema in her right eye, which had an IOP
of 56 mmHg. After administration of intravenous mannitol, the IOP fell to 14 mmHg and the corneal edema
disappeared. Subsequently, a glaucoma specialist performed laser iridotomy on the right eye.
Conclusions: Although AAC is a rare complication of intravitreal injection, it can occur in a patient with risk
factors such as hyperopic eye or narrow angle.
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Background
Intravitreal injections are extensively used to treat vari-
ous retinal diseases, and bevacizumab, a humanized
monoclonal anti-vascular endothelial growth factor
(VEGF) antibody is a common therapeutic agent for ex-
udative age-related macular degeneration and macular
edema resulting from diabetic retinopathy or retinal vein
occlusion (RVO). Because of its proven efficacy and rela-
tively low-cost, the adoption of intravitreal bevacizumab
injection is increasing in retinal clinics, and therefore,
the identification of its adverse effects is important.
Intravitreal injection has been reported to have several
complications, such as, intraocular inflammation, vitre-
ous hemorrhage, retinal detachment, endophthalmitis
and intraocular pressure (IOP) elevation [1]. Because of
the volume effect in the closed intravitreal cavity, IOP
elevation appears inevitable after an intravitreal injec-
tion. However, many authors agree IOP spikes after in-
travitreal injection are transient and that additional
intervention, such as anterior chamber (AC) paracentesis
is not required [2–4]. Nevertheless, IOP elevation may
induce morphologic change of AC angle which may
worsen outflow of aqueous humor. Here, we present a
case of acute angle closure (AAC) onset after intravitreal
bevacizumab injection in an eye with macular edema
resulting from branch retinal vein occlusion (BRVO).
Only one case report of AAC after intravitreal injection
in a patient with central retinal vein occlusion has been
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previously published [5], and to our knowledge, no case
of AAC after intravitreal injection in patient with BRVO
has been reported.
Case presentation
A 65-year-old woman was referred to the retina clinic of
tertiary referral center with decreased vision of 3 days dur-
ation in her right eye. She had no remarkable past medical
or family history. Her best corrected visual acuity was 0.15
in the right eye and 1.0 in the left. IOP was 19 mmHg in
both eyes. There was no afferent pupillary defect of right
or left pupils. On slit-lamp examination, sclera and con-
junctiva showed no injection, and there was no corneal
edema in either eye. AC was relatively shallow (3 corneal
thicknesses centrally, 1/4 corneal thicknesses peripherally)
in both eyes, and no inflammation was observed in either
eye. Lenses showed mild nuclear cataract in both eyes. A
gonioscopy exam demonstrated a narrow angle of over
180° in both eyes. The refractive error was +1.00 diopter
sphere in each eye. Dilated fundus exam revealed exten-
sive flame-shaped hemorrhage along the superotemporal
vein and macular edema in the right eye (Fig. 1). The optic
nerve head appeared normal with no evidence of glau-
comatous excavation and a cup-to-disc ratio of 0.5 in both
eyes. The remaining fundus examination was unremark-
able in the left eye.
Optical coherence tomography (OCT) depicted intrar-
etinal multiple cystic spaces and subretinal fluid (SRF)
around fovea in the right eye (Fig. 1). Central retinal
thickness (CRT) was 677 μm in the right eye. Fluores-
cein angiography of the right eye revealed a delayed fill-
ing time of the involved superior retinal vein.
Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected
into the right eye using a 30 gauge needle. The injection
site was pressed for 10 s with a cotton-tipped applicator to
prevent bevacizumab reflux. One month after this injec-
tion, the cystoid macular edema had almost regressed and
CRT was 256 μm. Visual acuity of the right eye had in-
creased to 0.5. To resolve the remaining edema and SRF,
second intravitreal bevacizumab injection was adminis-
tered to the right eye, and 1 month after this second injec-
tion, macular edema and SRF had regressed, CRT was
236 μm, and visual acuity was 0.6.
Five months after the second bevacizumab injection,
macular edema recurred and OCT showed intraretinal
multiple cystic spaces with a CRT of 479 μm. Visual
acuity was 0.5 in right eye. We immediately injected an
intravitreal bevacizumab a third time into the right eye.
All injections were performed by one retinal specialist
using the same method. After injetion, notable complica-
tions were not observed, and the patient did not com-
plain any symptoms at that time. Gross visual acuity was
routinely checked after injection and she was able to
count fingers.
The next day, the patient presented to our emergency
department complaining of persistent ocular pain. The
patient now mentioned that this pain had started after
the intravitreal injection. She also complained of head-
ache, nausea, and vomiting. At this presentation, visual
acuity was 0.08 in the right eye and 0.9 in the left. The
left pupil was normal but the right pupil was fixed and
mid-dilated (6 mm). A slit-lamp exam revealed diffuse
epithelial edema of cornea in the right eye. AC depth
was similar to that observed at her first visit (3 corneal
thicknesses centrally, 1/4 corneal thicknesses peripher-
ally) in both eyes (Fig. 2). IOP was 56 mmHg in the right
eye and 15 mmHg in the left. A diagnosis of acute
angle-closure glaucoma was made and she was immedi-
ately treated with 300 ml of 20% mannitol intravenously.
One hour after mannitolization, IOPs in right and left
eyes were 14 and 16 mmHg, respectively, and epithelial
edema of the right eye had decreased. Finally, a glau-
coma specialist performed laser iridotomy (LI) to the
right eye. After 3 days, prophylactic LI to the left eye
was performed to prevent the potential risk of AAC.
One month after LI, IOPs in right and left eyes were
13 and 15 mmHg, respectively, and iridotomy sites were
patent in both eyes. Visual acuity was 0.7 in the right
eye and 1.0 in the left. Automated visual field testing
was performed using the Humphrey 750i (Carl Zeiss
Fig. 1 Fundus photography (a) and OCT (b) of right eye; a Fundus
photography showing extensive flame-shaped hemorrhage along
the superotemporal retinal vein. b Optical coherence tomography
showing cystoid macular edema and subretinal fluid
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Meditec, Dublin, California, USA) with the 24–2 Swed-
ish interactive threshold algorithm (SITA) standard pro-
gram and no glaucomatous visual field defect was
evident in either eye. On dilated fundus examination,
the optic nerve showed no glaucomatous change in ei-
ther eye. Previous macular edema and flame-shaped
hemorrhage had almost disappeared in the right eye,
and OCT revealed normal peripapillary retinal nerve
fiber layer thickness in both eyes and no macular edema
in the right eye. Ocular biometry was performed using
IOL master (Carl Zeiss Meditec, Dublin, California,
USA). In right and left eyes, AC depths were 2.42 and
2.12 mm, respectively, and axial lengths were 22.64 and
22.50 mm, respectively.
Discussion and conclusions
This is likely the first case report to be issued on acute
angle closure after an intravitreal injection in branch
retinal vein occlusion.
Although the safety of intravitreal injection with
respect to IOP elevation has been established [2, 3],
some aspects require careful consideration. In previous
studies, most patients tolerated intravitreal injections
with IOP normalization within 30 min but a few cases
reached an IOP of ~80 mmHg immediately after injec-
tion [3, 6]. Because of these exceptional cases with ex-
treme IOP elevation, further studies are needed to
identify high risk patients and caution should be taken
when a patient is considered at risk.
The extreme IOP elevation can be explained by
biomechanical model, in which IOP elevation after intra-
vitreal injection may depend on the ocular biometric
characteristics of treated eye [7, 8]. According to this
theory, hyperopic eyes with short axial length and a
small intraocular volume are at greater risk of extreme
IOP elevation after intravitreal injection because they
may possess stiffer sclera rigidity, and a greater percent-
age of intraocular volume is introduced than in myopic
eyes with long axial length. Benz et al. reported an
association between immediate IOP changes and
vitreous reflux after intravitreal triamcinolone
acetonide injections [6], and noted eyes without vitre-
ous reflux showed greater IOP elevations than eyes
with reflux. In addition, eyes with preexisting
glaucoma took significantly longer after intravitreal
injection to achieve an IOP of < 30 mmHg [3].
In our case, the patient had a hyperopic eye of short
axial length and IOP normalization probably took longer
because of the presence of an outflow pathway abnor-
mality (narrow angle). Furthermore, the operator
prevented vitreous reflux by blocking the injected site
using a cotton-tipped applicator, which would have
contributed to IOP elevation.
Increased IOP may induce morphologic changes in the
AC because of forward movement of the iris and lens.
Alkin el al. reported an AC depth decrease (measured by
anterior segment OCT) 5 min after an intravitreal injec-
tion when the IOP was significantly higher than baseline
[9]. However, with time, the IOP normalized to baseline
and AC depth normalized and correlated with IOP level.
We presume anterior displacement of the anterior seg-
ment structure may have altered angle configuration and
result in further obstruction of aqueous humor outflow
pathway in our patient, and that this could have led to
an AAC attack followed by further rapid IOP elevation.
The mydriasis before intravitreal injection may also con-
tribute to the development of AAC attack. It has been
suggested in previous studies that mydriatic agents may
precipitate AAC attack in narrow angle patients [10].
Intravitreal bevacizumab injection is commonly used
to treat various retinal diseases but special care should
be taken when it is used to treat macular edema result-
ing from RVO for two reasons. The first is RVO may be
associated with narrow angle [11]. In a retrospective case
series study of 19 patients with RVO and narrow angle,
it was suggested angle closure should be considered as a
risk factor of RVO [12]. The authors recommended
angle status be checked when patients present with
RVO. The second reason is that despite the rarity of
AAC and the exceptional occurrence of AAC after intra-
vitreal injection [5], AAC is important because it can
cause irreversible optic nerve damage leading to visual
Fig. 2 Anterior segment photography of the right eye; a The pupil was mid-dilated and fixed. Corneal edema and punctate leison were observed.
b Central anterior chamber depth was about 3 corneal thicknesses. c Peripheral chamber depth was about 1/4 corneal thickness
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field loss and blindness [13]. Therefore, an evaluation of
angle configuration should be taken before intravitreal
injection, especially in the patients with RVO. If risk
factors such as narrow angle were identified, detailed
investigating symptoms or IOP check as well as gross
visual acuity assessment may be needed after intravit-
real injection.
In summary, IOP elevation after intravitreal injection
is usually non-hazardous. However, special caution is
needed in patients with predisposing factors such as
hyperopic eyes or narrow angle. Furthermore, because of
the possible association between narrow angle and RVO,
the angle status should be checked before administering
an intravitreal injection in RVO patients.
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